ReviewCureus2026
Advances in Positron Emission Tomography Combined With Computed Tomography (PET/CT) Imaging in Cervical Cancer: From Metabolic Assessment to Fibroblast Activation Protein-Targeted Imaging.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography combined with computed tomography (PET/CT) has transformed the staging and management of cervical cancer, extending far beyond conventional anatomical imaging. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/CT currently serves as the standard-of-care functional imaging modality for initial staging, nodal mapping, treatment response assessment, and surveillance; however, its utility is constrained by limited spatial resolution for small nodal metastases, suboptimal specificity in inflammatory lesions, physiological urinary tracer excretion obscuring pelvic disease, and inability to characterize tumor microenvironmental composition. These limitations have driven the development of fibroblast activation protein inhibitor (FAPI) PET/CT, which capitalizes on the overexpression of fibroblast activation protein within the cancer-associated stroma of cervical tumors. FAPI-based imaging offers superior tumor-to-background contrast, improved delineation of primary lesions and metastatic deposits, and promising theranostic potential. This review traces the evolution from ¹⁸F-FDG metabolic imaging to FAPI-targeted PET/CT, reflecting a broader paradigm shift toward molecularly informed imaging in cervical cancer. Future directions include prospective clinical validation, radiomics integration, and the role of FAPI-PET in guiding adaptive radiotherapy and systemic treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.